1. Home
  2. Documents
  3. VI Conference of the Pan American Network for Drug Regulatory Harmonization. Brasília, Brasil, 6-8 July, 2011.

VI Conference of the Pan American Network for Drug Regulatory Harmonization. Brasília, Brasil, 6-8 July, 2011.

Download

Only in Spanish.

VI CPANDRH 

The Pan American Conference on Drug Regulatory Harmonization (CPANDRH) is held every two or three years. Its mission, "to promote drug regulatory harmonization for all aspects of quality, safety, and efficacy of pharmaceutical products as a contribution to the quality of life and health care of the citizens of the Member Countries of the Americas," is mentioned in the most recent statutes of the Pan American Network for Drug Regulatory Harmonization (PANDRH), approved by its Steering Committee in June 2009.

The VI Pan American Conference on Drug Regulatory Harmonization was held at the headquarters of the National Health Surveillance Agency (ANVISA) located in Brasilia, Brazil, from July 6-8, 2011. Its theme was "Strengthening National Health Regulatory Authorities." The Conference opened in the presence of high national public health authorities and PAHO officials, with over 300 participants from 26 countries of the Americas in attendance. This conference was an important venue for national authorities, experts, and representatives of the pharmaceutical industry and PAHO/WHO to share their views about regulatory issues of great import in public health, searching for strategies to advance drug regulatory harmonization in the Region of the Americas.

The topics addressed during the Conference included the role of PANDRH as coordinator of international cooperation, PAHO's recognition of national regulatory reference authorities (ANMAT—Argentina, ANVISA-Brazil, INVIMA-Colombia, and CECMED-Cuba), implementation of the PANDRH guidelines in the subregions, and innovative activities of the national regulatory agencies (NRA) in surveillance or treatment compliance, as well as the papers and other documents produced by the PANDRH Working Groups on Good Laboratory Practices, Biotechnology Products, Drug Registration, and Counterfeit Drugs and plenary.

This important meeting came to a close on Friday, July 8, with the approval of a strategic orientations document. The main recommendations, which fall within the framework of PAHO Resolution CD50.R9, Strengthening National Regulatory Authorities for Medicines and Biologicals, are aimed at developing more effective cooperation among countries to guarantee, inter alia, the adoption and implementation of the different technical documents produced by the National Regulatory Authorities (NRAs).